CN117567610A - 酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 - Google Patents
酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 Download PDFInfo
- Publication number
- CN117567610A CN117567610A CN202311574272.8A CN202311574272A CN117567610A CN 117567610 A CN117567610 A CN 117567610A CN 202311574272 A CN202311574272 A CN 202311574272A CN 117567610 A CN117567610 A CN 117567610A
- Authority
- CN
- China
- Prior art keywords
- casein
- polypeptide
- protein
- type
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005018 casein Substances 0.000 title claims abstract description 68
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 title claims abstract description 68
- 235000021240 caseins Nutrition 0.000 title claims abstract description 68
- 238000001514 detection method Methods 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 9
- 229920001184 polypeptide Polymers 0.000 claims abstract description 36
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 36
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 36
- 238000012216 screening Methods 0.000 claims abstract description 17
- 101000978703 Escherichia virus Qbeta Maturation protein A2 Proteins 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims abstract description 14
- 108091007433 antigens Proteins 0.000 claims abstract description 14
- 102000036639 antigens Human genes 0.000 claims abstract description 14
- 230000008878 coupling Effects 0.000 claims abstract description 6
- 238000010168 coupling process Methods 0.000 claims abstract description 6
- 238000005859 coupling reaction Methods 0.000 claims abstract description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 235000018102 proteins Nutrition 0.000 claims description 28
- 102000004169 proteins and genes Human genes 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 12
- 238000002965 ELISA Methods 0.000 claims description 8
- 241000699670 Mus sp. Species 0.000 claims description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
- 238000003556 assay Methods 0.000 claims description 6
- 239000011248 coating agent Substances 0.000 claims description 6
- 238000000576 coating method Methods 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 6
- 239000010931 gold Substances 0.000 claims description 6
- 229910052737 gold Inorganic materials 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 5
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000000020 Nitrocellulose Substances 0.000 claims description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 4
- 229910052782 aluminium Inorganic materials 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 229920001220 nitrocellulos Polymers 0.000 claims description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 238000010255 intramuscular injection Methods 0.000 claims description 3
- 239000007927 intramuscular injection Substances 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108010076119 Caseins Proteins 0.000 abstract description 64
- 102000011632 Caseins Human genes 0.000 abstract description 63
- 235000013336 milk Nutrition 0.000 abstract description 28
- 239000008267 milk Substances 0.000 abstract description 28
- 210000004080 milk Anatomy 0.000 abstract description 28
- 235000021247 β-casein Nutrition 0.000 abstract description 15
- 238000009395 breeding Methods 0.000 abstract description 4
- 230000001488 breeding effect Effects 0.000 abstract description 4
- 230000007910 cell fusion Effects 0.000 abstract description 4
- 210000004408 hybridoma Anatomy 0.000 abstract description 3
- 238000002347 injection Methods 0.000 abstract description 3
- 239000007924 injection Substances 0.000 abstract description 3
- 108010000912 Egg Proteins Proteins 0.000 abstract description 2
- 239000012634 fragment Substances 0.000 abstract description 2
- 229920002521 macromolecule Polymers 0.000 abstract description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 241000283690 Bos taurus Species 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 4
- RKYJTDSQXOMDAD-JKXTZXEVSA-N (2s,3s)-2-[[(2s)-1-[2-[[(2s)-1-[(2s)-2-[[(2s)-1-[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]acetyl]pyrrolidine-2-carbonyl]amino]-3-methylpentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H]1N(C(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CC=2C=CC(O)=CC=2)CCC1 RKYJTDSQXOMDAD-JKXTZXEVSA-N 0.000 description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 108010020546 beta-casomorphin 7 Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 2
- 239000004327 boric acid Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101150109698 A2 gene Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 102100038920 Alpha-S1-casein Human genes 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102100035606 Beta-casein Human genes 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 101150055928 CSN1S2 gene Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010067715 Gastrointestinal sounds abnormal Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000741048 Homo sapiens Alpha-S1-casein Proteins 0.000 description 1
- 101000947120 Homo sapiens Beta-casein Proteins 0.000 description 1
- 101000726004 Homo sapiens COP9 signalosome complex subunit 2 Proteins 0.000 description 1
- 101000726002 Homo sapiens COP9 signalosome complex subunit 3 Proteins 0.000 description 1
- 101000793859 Homo sapiens Kappa-casein Proteins 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 235000020185 raw untreated milk Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54346—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4731—Casein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及酪蛋白变体A1和A2的单克隆抗体在制备酪蛋白表型检测试剂中的应用,属于生物化学领域。通过生物信息手段检索A1型和A2型β‑酪蛋白的多肽序列,筛选特异性多肽片段作为半抗原,通过与大分子偶联形成免疫抗原,用A1型和A2型β‑酪蛋白作为筛选抗原。利用免疫注射和杂交瘤细胞融合的方式获得β‑酪蛋白变体A1蛋和A2蛋白单克隆抗体株。制备所得抗体可用于A1和A2蛋白快速检测卡的开发,对奶源筛查和奶牛选育具有重要意义。
Description
技术领域
本发明属于生物化学领域,涉及酪蛋白变体A1和A2的单克隆抗体在制备酪蛋白表型检测试剂中的应用。
背景技术
随着人们对营养健康的重视程度与日俱增,大众对牛奶的品质也提出了更高的要求。牛奶中有矿物质、脂溶性维生素和各种蛋白质,其最主要功效是为人体提供钙离子和丰富的蛋白质。牛奶蛋白中有约80%的酪蛋白和20%的乳清蛋白,酪蛋白是牛奶中最主要的蛋白质,分有αs1、αs2、β和κ四类亚型,分别由位于牛6号染色体上的CSN1S1、CSN1S2、CSN2和CSN3基因编码。酪蛋白约占总蛋白质含量的36%,主要功能是运输磷酸钙。在牛奶酪蛋白12种变体(A1,A2,A3,B,C,D,E,F,H1,H2,I,和G)中,最常见的A1和A2变体。有研究认为,酪蛋白变体A1是乳糖不耐受的致病主源,同时可能是Ⅰ型糖尿病、婴儿猝死综合征和心血管疾病的危险因素,这与A1蛋白的水解产物β-酪啡肽7(BCM-7)有关。不同的是,A2变体蛋白的摄入并不会引起人体过多的不良反应,在β-酪蛋白A2变体的水解牛奶中不存在BCM-7。基于β-酪蛋白基因多态性,一项关于A2β-酪蛋白牛奶对人体肠道健康的影响研究显示,志愿者在饮用A2酪蛋白牛奶2周后,肠道双歧杆菌的丰度比入组时显著提高。A2酪蛋白牛奶较明显地降低了志愿者腹胀、肠鸣比例,增加了正常排便频率。
尽管对于变体A蛋白的更多机制有待深入研究。目前研究表明A2-β酪蛋白牛奶更接近于母乳,更贴合人体的消化系统。
2000年,CorporationLtd.在新西兰成立,该公司就以A2基因检测和售卖A2变体牛奶盈利。随着全球化的发展,A2牛奶的市场逐渐扩大,目前在中国、澳大利亚、英国、美国、新西兰和荷兰等许多国家都可以买到β-酪蛋白A2变体的新生儿配方奶粉。不足的是,在国内少有A2变体牛奶自主开发产品,A2产业在国内的发展具有广大商业前景。拥有A2奶源,甄选高品质安全生奶是更多大企业的发展趋势。
目前上市A2奶粉的奶源控制以A2纯种奶牛的选育为主导,通过A变体基因型的核酸测序和变体蛋白质的检测实现。测序基因分型和等位基因特异性聚合酶链式反应是监测奶牛β-酪蛋白变异基因的一种准确可靠的方法,而奶粉则需要通过高效液相色谱法、等电聚焦电泳法、质谱和毛细管电泳等方法实现检测。这些方法均需要用到仪器,检测步骤繁多,样品处理要求高,成本高,检测时间长。若能用利用免疫学原理制备A1和A2蛋白的检测卡,有望使检测更加便捷快速,且结果精准,检测成本最低。
开发A1和A2的单克隆抗体能解决我国在A2奶源检测试剂盒方面的需求缺口,能快速可靠检测牛奶中的酪蛋白表型,有助于A2牛奶食品工业的应用。
发明内容
针对上述问题,本发明通过酪蛋白变型创新开发A1和A2的单克隆抗体,所得抗体可有效应用于A1和A2蛋白快速检测卡的开发,对奶源筛查和奶牛选育具有重要意义。
本发明采用的具体方案为:
第一方面,一种酪蛋白变体A1和A2蛋白的单克隆抗体的制备方法,包括以下步骤:
步骤一、对比A1蛋白和A2蛋白的同源蛋白,对两个蛋白序列进行分析,氨基酸序列如SEQ ID NO:1所示的A1蛋白的第67个氨基酸是一个组氨酸,而氨基酸序列如SEQ ID NO:2所示的A2是一个脯氨酸,以第67个氨基酸为中心设计并合成两段多肽序列,分别针对A1和A2型酪蛋白,多肽长度为7-15个氨基酸;
步骤二、免疫抗原采用合成的多肽与大分子蛋白进行共价偶联获得,筛选抗原采用A1酪蛋白、A2酪蛋白;
步骤三、小鼠免疫采用多点皮下法或肌肉注射法,佐剂为佛氏佐剂或铝佐剂;
步骤四、采用PEG进行B细胞与骨髓瘤细胞的融合,HAT筛选后,用A1酪蛋白、A2酪蛋白包被的ELISA方法筛选,最后分别得到A1酪蛋白、A2酪蛋白的单克隆抗体株。
作为对上述制备方法的进一步优化,步骤一中,所述多肽的长度为9-12个氨基酸。更进一步地,针对A1型酪蛋白的多肽序列如SEQ ID NO:3所示,针对A2型酪蛋白的多肽序列如SEQ ID NO:4所示。
作为对上述制备方法的进一步优化,步骤二中,所述大分子蛋白为KLH、BSA或OVA。
第二方面,酪蛋白变体A1和A2的单克隆抗体在制备酪蛋白表型检测试剂中的应用,针对A1型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:3所示的多肽制备;针对A2型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:4所示的多肽制备。
第三方面,一种酪蛋白表型检测试剂卡,包含酪蛋白变体A1和A2的单克隆抗体,其中,针对A1型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:3所示的多肽制备,针对A2型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:4所示的多肽制备。进一步地,所述检测试纸卡由样品垫、金标垫、硝酸纤维素膜、吸水垫和底板组成。
有益效果:本发明通过生物信息手段检索A1型和A2型β-酪蛋白的多肽序列,筛选特异性多肽片段作为半抗原,通过与大分子偶联形成免疫抗原,用A1型和A2型β-酪蛋白作为筛选抗原。利用免疫注射和杂交瘤细胞融合的方式获得β-酪蛋白变体A1蛋和A2蛋白单克隆抗体株。制备所得抗体可用于A1和A2蛋白快速检测卡的开发,对奶源筛查和奶牛选育具有重要意义。
附图说明
图1是酪蛋白变体A1蛋白和A2蛋白单克隆抗体筛选结果图。
图2是检测卡的灵敏度检测结果图。
图3是A1/A2不同质量比下检测卡的特异性检测结果图;其中,从左到右对应的A1/A2的质量比依次为1∶10000、1∶1000、1∶500、1∶100。
图4是A2/A1不同质量比下检测卡的特异性检测结果图;其中,从左到右对应的A2/A1的质量比依次为1∶10000、1∶1000、1∶500、1∶100。
具体实施方式
本发明提供一种A1蛋白和A2蛋白的单克隆抗体及制备方法。
1、通过生信检索,对比A1蛋白(氨基酸序列如SEQ ID NO:1所示)、A2蛋白(氨基酸序列如SEQ ID NO:2所示)的同源蛋白,对两个蛋白序列进行分析,A1的第67个氨基酸是一个组氨酸,而A2是一个脯氨酸,因此以第67个氨基酸为中心设计两段多肽序列,分别针对A1和A2型酪蛋白,多肽长度为7-15个,以9-12个为优。设计结果如下表1所示。
表1两段多肽序列
A2酪蛋白 | PGPIPNSLP |
A1酪蛋白 | PGPIHNSLP |
2、免疫抗原采用合成的多肽与大分子蛋白,如KLH、BSA、OVA等,进行共价偶联获得。筛选抗原采用市面销售奶粉中的A1酪蛋白、A2酪蛋白。
3、小鼠免疫采用多点皮下法或肌肉注射法,佐剂为佛氏佐剂或铝佐剂。
4、采用PEG进行B细胞与骨髓瘤细胞的融合,HAT筛选后,用A1酪蛋白、A2酪蛋白包被的ELISA方法筛选,最后得到分别得到A1酪蛋白、A2酪蛋白的单克隆抗体株。
下面将结合本发明实施例,对本发明的技术方案进行清楚、完整地描述。
如非特别说明,下述实施例所用试剂或材料均为常规市售,所用操作手段均为常规技术。
实施例1
一、免疫抗原和检测抗原的制备
1、将2种多肽、KLH、EDC分别用50mM MES缓冲液(PH6)溶解,终浓度分别为1mg/mL,5mg/mL及500mg/mL。
2、取500μL的多肽溶液加入到1mL的KLH溶液中并混合,并往里缓慢滴加100μLEDC溶液,边滴加边振荡,并置于磁力搅拌器室温反应2h,使多肽和KLH进行偶联。
3、反应结束后,将混合物加入15kDa的透析袋中,4℃下用1L的PBS中透析5次,除去偶联副产物,换液间隔为4-6h。
4、收集透析后的多肽-KLH偶联物。
二、小鼠免疫
4只6-8周龄BALB/c雌性小鼠,采用皮下多点免疫。
表2小鼠免疫流程表
表1中,抗原与铝佐剂按照1:1体积混合,融合前三天的加强免疫不加佐剂腹腔注射。
三、ELISA血清和培养上清检测
1、抗原包被:将A1或A2酪蛋白用碳酸盐包被缓冲液(无水碳酸钠63.6克及碳酸氢钠33.6克溶于蒸馏水中稀释至1000mL)稀释到5μg/mL,100μL/孔,包被96孔板,然后37℃恒温恒湿孵育2h。
2、封闭:孵育2h后倒弃包被液,用含有0.1%BSA的PBS进行封闭,每孔200μL,37℃孵育2h。
3、洗涤:每孔用200μL的PBST洗3次,并拍干。
4、加样:小鼠的血清分别用PBS稀释4-12万倍后,取于100μL加入96孔板,37℃孵育20min。融合细胞筛选直接取细胞培养板内100μL的培养上清加入ELISA板即可。
5、洗涤:将酶标板内的待测血清(或培养上清)倒空,每孔用200μL的PBST洗3次,并拍干。
6、二抗:HRP标记的兔抗鼠IgG抗体用PBS稀释2000倍后,每孔加入100μL,37℃孵育20min。
7、洗涤:倒弃二抗溶液,每孔用200μL的PBST洗3次,并拍干。
8、显色:每孔加入显色液100μL,置于室温下显色10min。
9、终止:每孔加入终止液50μL,并于450nm酶标仪检测OD值。
10、取血清效价60000以上的小鼠进行融合。
四、细胞融合
1、脾淋巴细胞的制备
拉颈处死免疫小鼠,75%的酒精浸泡消毒3min。无菌取出脾脏,用DMEM不完全培养基清晰外层后置于小培养皿内,用5mL注射器往脾脏内注入培养基,冲出脾脏内细胞,通过多次注射直至脾脏颜色从深红变为微红。1200rpm离心5min收集脾细胞,用DMEM不完全培养基重悬并计数。
2、细胞融合
从培养皿收集SP2/0骨髓瘤细胞,按照骨髓瘤细胞:脾细胞=1:10的比例混合均匀,离心清洗2次(1000rpm,5min)。完全去除无血清培养基,轻轻敲打离心管,边转边敲打,将细胞沉淀完全分散。将离心管置于加了37℃水的250mL烧杯中,轻微摇晃2min后缓慢滴加1mL的50%PEG,静置60s进行融合。90s后缓慢滴加37℃的不完全DMEM 30mL,900rpm离心5min收集细胞。HAT完全培养基(15%小牛血清)重悬细胞,100μL/孔加入饲养细胞的培养板,隔2天换液,7天后更换为HT培养基,13天后换成正常完全培养基。待融合的细胞克隆长满10%孔底的时候进行上清中抗体检测,具体ELISA血清和培养上清检测所述。
3、细胞亚克隆
采用有限稀释法进行亚克隆。提前一天按照前述制备好饲养细胞。在显微镜下用油性笔对筛选到的阳性克隆做标记,用10μL的移液枪把克隆吸出后用HT培养基梯度稀释,每孔100μL加入到饲养细胞板中,每个梯度1排。培养7~10天,每2天换液,在肉眼观察到克隆后再次检测上清中抗体,再将阳性孔内的细胞继续扩大培养并冻存。
4、采用β-酪蛋白(A1和A2型均可)通过弗氏佐剂乳化,背部皮下6多注射兔子,连续3次注射,每次间隔10天,然后心脏取血,分离血清后用蛋白A柱纯化兔β-酪蛋白多抗。
5、ELISA检测
杂交瘤细胞培养上清用蛋白A柱纯化后,采用高碘酸法偶联HRP。具体如下:
①称取1mg HRP溶解于1ml蒸馏水中。
②于上液中加入0.2ml新配的0.1M NaIO4溶液,室温下避光搅拌20分钟。
③将上述溶液用15KD的超滤管过滤。
④用1ml的10mM(PH9.5)碳酸盐缓冲液重悬,取100ul分别加入1ml的0.1mg/ml的A1或A2抗体的碳酸盐缓冲液中(0.01M),室温避光轻轻搅拌2小时。
⑤加0.03ml新配的4mg/ml NaBH4液,混匀,再置4℃2小时。
⑥将上述溶液用15KD的超滤管过滤,用500ul PBS重悬。
⑦抗体棋盘杂交:采用100ul 5ug/ml的兔β-酪蛋白多克隆抗体包板,封闭后与0.5-4ug/ml的A1或A2酪蛋白反应,清洗3次后分别加入HRP标记的兔抗鼠抗体,37℃反应5min后清洗显色,结果如图1所示。
实施例2
一种快速检测试剂卡:包括如下组分:
1、用于使检测样品显色的胶体金,所述胶体金标标记发明中针对酪蛋白变体A1或A2的单克隆抗体。标记条件为PH 8.5,标记量为5ug/ml,室温标记半小时后采用1%的BSA进行室温封闭1小时(终浓度0.01%)。4℃,12000rpm离心15min,收集金沉淀后用20mM的硼酸缓冲液(PH 7.5,1%BSA,1%蔗糖)重悬,并喷涂在玻璃纤维上干燥。
2、检测线用酪蛋白的兔多克隆抗体(1mg/ml)划线,质控线为兔抗鼠多抗(1mg/ml)划线。样品垫采用20mM的硼酸缓冲液浸泡后干燥处理(PH 7.5,1%BSA,1%蔗糖,0.75%曲拉通-100)。
3、检测卡由样品垫、金标垫、硝酸纤维素膜、吸水垫和底板组成。样品垫、金标垫、硝酸纤维膜、吸水纸按照2-3mm重叠依次黏贴在底衬上,并用切条机且为3mm条子,包装后干燥室温保存。
4、检测卡对A1和A2酪蛋白的灵敏度均为50ng/ml,结果如2所示。
5、针对特异性,检测卡依次对A2/A1和A1/A2质量比为1:10000,1:1000,1:500和1:100的奶粉按10mg/ml溶解在PBS中进行检测,其结果如图3和图4所示,A1/A2比例为1:10000可检测到微量的A1蛋白(图3),A2/A1比例为1:1000可检测到微量的A2蛋白(图4)。
需要说明的是,以上所述的实施方案应理解为说明性的,而非限制本发明的保护范围,本发明的保护范围以权利要求书为准。对于本领域技术人员而言,在不背离本发明实质和范围的前提下,对本发明作出的一些非本质的改进和调整仍属于本发明的保护范围。
Claims (7)
1.一种酪蛋白变体A1和A2蛋白的单克隆抗体的制备方法,其特征在于:包括以下步骤:
步骤一、对比A1蛋白和A2蛋白的同源蛋白,对两个蛋白序列进行分析,氨基酸序列如SEQ ID NO:1所示的A1蛋白的第67个氨基酸是一个组氨酸,而氨基酸序列如SEQ ID NO:2所示的A2是一个脯氨酸,以第67个氨基酸为中心设计并合成两段多肽序列,分别针对A1和A2型酪蛋白,多肽长度为7-15个氨基酸;
步骤二、免疫抗原采用合成的多肽与大分子蛋白进行共价偶联获得,筛选抗原采用A1酪蛋白、A2酪蛋白;
步骤三、小鼠免疫采用多点皮下法或肌肉注射法,佐剂为佛氏佐剂或铝佐剂;
步骤四、采用PEG进行B细胞与骨髓瘤细胞的融合,HAT筛选后,用A1酪蛋白、A2酪蛋白包被的ELISA方法筛选,最后分别得到A1酪蛋白、A2酪蛋白的单克隆抗体株。
2.根据权利要求1所述的制备方法,其特征在于:步骤一中,所述多肽的长度为9-12个氨基酸。
3.根据权利要求2所述的制备方法,其特征在于:针对A1型酪蛋白的多肽序列如SEQ IDNO:3所示,针对A2型酪蛋白的多肽序列如SEQ ID NO:4所示。
4.根据权利要求1所述的制备方法,其特征在于:步骤二中,所述大分子蛋白为KLH、BSA或OVA。
5.酪蛋白变体A1和A2的单克隆抗体在制备酪蛋白表型检测试剂中的应用,针对A1型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:3所示的多肽制备;针对A2型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:4所示的多肽制备。
6.一种酪蛋白表型检测试剂卡,其特征在于:包含酪蛋白变体A1和A2的单克隆抗体,其中,针对A1型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:3所示的多肽制备;针对A2型酪蛋白的单克隆抗体采用氨基酸序列如SEQ ID NO:4所示的多肽制备。
7.根据权利要求6所述的检测试纸卡,其特征在于:所述检测试纸卡由样品垫、金标垫、硝酸纤维素膜、吸水垫和底板组成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311574272.8A CN117567610A (zh) | 2023-11-23 | 2023-11-23 | 酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311574272.8A CN117567610A (zh) | 2023-11-23 | 2023-11-23 | 酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117567610A true CN117567610A (zh) | 2024-02-20 |
Family
ID=89885858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311574272.8A Pending CN117567610A (zh) | 2023-11-23 | 2023-11-23 | 酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117567610A (zh) |
-
2023
- 2023-11-23 CN CN202311574272.8A patent/CN117567610A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1731907B1 (en) | Method of detecting allergen | |
EP0864865B1 (en) | Method for measuring glycated hemoglobin | |
CN101413955B (zh) | 一种检测玉米赤霉烯酮的elisa测试盒及制备及检测方法 | |
US6849419B1 (en) | Monoclonal antibody hybridoma immunoassay method and diagnosis kit | |
CN110616195A (zh) | 一株二甲双胍单克隆抗体杂交瘤细胞株及其应用 | |
CN110713986B (zh) | 一株维生素b1单克隆抗体杂交瘤细胞株cbdd及其应用 | |
JP7013051B2 (ja) | 牛妊娠関連グリコタンパク質1に特異的に結合する抗体及びその用途 | |
CN109810191B (zh) | 一种抗羊骨骼肌肌钙蛋白i单克隆抗体及其应用 | |
CN112375744A (zh) | 一株二氢吡啶单克隆抗体杂交瘤细胞株及其应用 | |
CN101580545B (zh) | 抗h5n1来源的血凝素蛋白的单克隆抗体及其应用 | |
CN111171138B (zh) | 用于检测刺参低聚肽的肽段、单克隆抗体、胶体金试纸条及检测方法 | |
CN111334479A (zh) | 一株氯羟吡啶单克隆抗体杂交瘤细胞株tyl及其应用 | |
CN117567610A (zh) | 酪蛋白变体a1和a2的单克隆抗体在制备酪蛋白表型检测试剂中的应用 | |
CN111454912B (zh) | 一株赛拉嗪单克隆抗体杂交瘤细胞株及其应用 | |
CN113046325B (zh) | 一株维生素k3单克隆抗体杂交瘤细胞株及其应用 | |
CA1302920C (en) | Monoclonal antibody to okadaic acids, process for producing the monoclonal antibody, assay reagent for assaying okadaic acids using the monoclonal antibody, and assay method | |
GB2133543A (en) | Monoclonal antibody specific to human melanoma | |
CN108132348B (zh) | 苏丹红iii半抗原、偶联抗原、抗体及胶体金快速检测装置及其用途 | |
JP4597172B2 (ja) | ウシミオグロビン部分ペプチドに対する抗体、及び当該抗体を用いた検査方法並びに検査用キット | |
CN112574302A (zh) | 杂交瘤细胞lcz8a3及其分泌的单克隆抗体和应用 | |
CN118393137B (zh) | 一种肠道保护菌的检测试剂盒及其应用 | |
Kline et al. | Immunochemical characterization of differentiation and age-related cell surface antigens expressed by chicken erythrocytes | |
US5707878A (en) | Method for detecting blood component using conidiobolus hemagglutinin | |
CN116375606B (zh) | 降糖类药品和保健品中苯乙双胍的快速检测装置及其制备和应用 | |
WO1998024885A1 (en) | Helicobacter pylori antigen having an apparent molecular weight of 16±2 kda, a specific antibody, and its use for the detection of said antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |